2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-156989
    Butobendine 55769-65-8 98%
    Butobendine, a double ester of 2-aminobutanol and trimethoxybenzoic acid, is an antiarrhythmic agent. Butobendine is a noncompetitive inhibitor of dopamine β-hydroxylase (DBH).
    Butobendine
  • HY-157129
    AMPK-α1β1γ1 activator 1 1943510-86-8 98%
    AMPK-α1β1γ1 activator 1 (M1) is an acyl glucuronide metabolite of Indole-3-carboxylic Acid-based AMPK activator. AMPK-α1β1γ1 activator 1 can selectively activated human β1 isoforms with an EC50 value of 38.1nM. AMPK-α1β1γ1 activator 1 can direct binding with human AMPK α1β1γ1 isoform. AMPK-α1β1γ1 activator 1 can be used for the research of diabetic nephropathy.
    AMPK-α1β1γ1 activator 1
  • HY-157195
    Smurf-1-IN-3 1825312-08-0 98%
    Smurf-1-IN-3 is a selective Smurf-1 inhibitor with an IC50 value of 2.2 nM. Smurf-1-IN-3 can be used for the research of pulmonary arterial hypertension.
    Smurf-1-IN-3
  • HY-157420
    VEGFR-2-IN-38 3020790-57-9 98%
    VEGFR-2-IN-38 (compound 3) is a potential vascular endothelial growth factor receptor-2 inhibitor.
    VEGFR-2-IN-38
  • HY-157461
    Glycation-IN-1 3023711-86-3 98%
    Glycation-IN-1 (Compound 3) is an inhibitor of glycosylation reactions, which has a strong inhibitory effect on the synthesis of initial, intermediate, and final products of glycosylation reactions. Glycion-IN-1 can be used in the research of various chronic diseases, such as diabetes, immune inflammation, cardiovascular diseases and neurodegenerative diseases.
    Glycation-IN-1
  • HY-15746R
    Dobutamine hydrochloride (Standard) 49745-95-1 98%
    Dobutamine (hydrochloride) (Standard) is the analytical standard of Dobutamine (hydrochloride). This product is intended for research and analytical applications. Dobutamine hydrochloride is a synthetic catecholamine that acts on α1-AR, β1-AR, β2-AR (α-1, β-1 andβ-2 adrenoceptors). Dobutamine hydrochloride is a selective β1-AR agonist, relatively weak activity at α1-AR and β2-AR. Dobutamine hydrochloride can increase cardiac output and correct hypoperfusion.
    Dobutamine hydrochloride (Standard)
  • HY-157538
    PDK4-IN-2 1616752-12-5 98%
    PDK4-IN-2 (compound 8) is a pyruvate dehydrogenase kinase 4 (PDK4) inhibitor with an IC50 of 46 µM. PDK4-IN-2 improves ejection fraction of failing hearts by regulating bioenergetics via activation of the tricarboxylic acid cycle.
    PDK4-IN-2
  • HY-157577
    PROTAC(H-PGDS)-8 2761281-51-8 98%
    PROTAC(H-PGDS)-8 is a Hematopoietic prostaglandin D synthase (H-PGDS) PROTAC degrader, with a IC50 of 0.14 μM.
    PROTAC(H-PGDS)-8
  • HY-157658
    K-8794 180577-26-8 98%
    K-8794 is an orally active selective endothelin receptor ETB antagonist that can be used in research on cardiovascular diseases.
    K-8794
  • HY-157874
    Eoxin A4 81918-96-9
    Eoxin A4 (14,15-Leukotriene A4) is an Arachidonic acid (HY-109590) metabolite. Eoxin A4 forms via the 15-lipoxygenase pathway.
    Eoxin A4
  • HY-157930
    TP-2 98%
    TP-2, a caltrop-like multicationic small molecule, is an antidote that can completely neutralize both unfractionated heparin (UFH) and low-molecular-weight heparins (LMWHs). TP-2 is not only superior to protamine, has higher neutralization activity, but is also biocompatible.
    TP-2
  • HY-158722
    Caerulein acetate 2760881-68-1 98%
    Caerulein acetate is a decapeptide and a potent cholecystokinin receptor agonist. Ceruletide acetate is a safe and effective cholecystokinetic agent with a direct spasmogenic effect on the gallbladder muscle and bile ducts.
    Caerulein acetate
  • HY-15876R
    Clopidogrel thiolactone (Standard) 1147350-75-1
    Cyhalofop (Standard) is the analytical standard of Cyhalofop. This product is intended for research and analytical applications. Cyhalofop (Cyhalofop acid), the primary metabolite of Cyhalofop-butyl (HY-B0861) in susceptible grasses, is the herbicidally active metabolite. Cyhalofop-butyl is an aryloxyphenoxypropionate post-emergence herbicide widely used around the world in agriculture.
    Clopidogrel thiolactone (Standard)
  • HY-15893G
    DMOG (GMP) 89464-63-1 98%
    DMOG (GMP) is the GMP level of DMOG (HY-15893). GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. DMOG (GMP) is a HIF-1α stabilizer. DMOG (GMP) promotes the osteogenic, angiogenic, and chondrogenic differentiation of stem cells by stabilizing the expression of HIF-1α. DMOG (GMP) can enhance the osteogenic and angiogenic differentiation potential of stem cells, thereby improving bone regeneration in bone defects. DMOG (GMP) can be used in the research of bone defect repair, vascularized bone regeneration, and the treatment of bone-related diseases (such as osteoporosis and femoral head necrosis) .
    DMOG (GMP)
  • HY-159090
    AT1R antagonist 3 3053482-15-5 98%
    AT1R antagonist 3 (Compound 1) is an antagonist for angiotensin II type 1 receptor (AT1R) and an inhibitor for calcium channel type-L CaV1.2 (IC50=0.57 μM). AT1R antagonist 3 exhibits vasodilation efficacy in solated rat aorta (10 μM, 88.7%) and antihypertensive efficacy in rat models.
    AT1R antagonist 3
  • HY-159567
    Ferroptosis-IN-11 1266755-01-4 98%
    Ferroptosis-IN-11 (compound 43) is a ferroptosis inhibitor. Ferroptosis-IN-11 can inhibit Erastin (HY-15763) induced ferroptosis in HT-1080 human fibroblasts (EC50=36 nM). Ferroptosis-IN-11 can be used in the study of cardiovascular disease and neurodegeneration.
    Ferroptosis-IN-11
  • HY-159582
    ACKR3 agonist 1 98%
    ACKR3 agonist 1 (compound 27) is a selective ACKR3 agonist (EC50=69 nM, Emax=82%) that inhibits platelet aggregation. ACKR3 agonist 1 is metabolically stable and non-cytotoxic, and has the potential to inhibit platelet-mediated thrombosis.
    ACKR3 agonist 1
  • HY-159698
    IONIS-DGAT 2Rx 2091332-22-6 98%
    IONIS-DGAT 2Rx (ION-224) is a DGAT2 inhibitor, which is promising for research of atherosclerosis.
    IONIS-DGAT 2Rx
  • HY-159704
    9-Keto-latanoprost 141074-06-8 98%
    9-keto latanoprost is a derivative of the F-prostaglandin (FP) receptor agonist Latanoprost (HY-B0577).
    9-Keto-latanoprost
  • HY-159707
    MCL1020 2309309-69-9
    MCL1020 is a CHK1 inhibitor with an IC50 of 1.61 μM. MCL1020 properly occupies the ATP pocket by interacting with a diverse range of the sites of CHK1 kinase. MCL1020 can be used for the study of hematologic malignancies.
    MCL1020
Cat. No. Product Name / Synonyms Application Reactivity